

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

A COMPARATIVE STUDY OF THE EFFECT OF PROPOFOL AND ETOMIDATE AS AN INDUCTION AGENT ON HAEMODYNAMIC CHANGES DURING INDUCTION AND ENDOTRACHEAL INTUBATION

Dr Bhavini Shah¹, Dr Shweta Birajdar ^{2*}

¹Professor Dept Anesthesiology Dr D.Y.Patil Medical College Hospital and Research Centre
Pimpri Pune, Dr D.Y.Patil Vidyapeeth Pimpri Pune Maharashtra – 411018, India.

²Third Year Junior Resident, Dept of Anesthesiology, Dr D.Y.Patil Medical College Hospital
India and Research Centre Pimpri Pune, Dr D.Y.Patil Vidyapeeth Pimpri Pune Maharashtra-
411018 – India

ABSTRACT

Aims: Presently Propofol and Etomidate are popular as rapid acting inducing agents. Due to reflex sympathetic stimulation, direct laryngoscopy and endotracheal intubation typically cause a cardiovascular stress response characterised by hypertension and tachycardia. This study is conducted to compare the effects of these two drugs on hemodynamic responses during induction and endotracheal intubation, to compare time of induction to choose the better induction agent and to study adverse effects of the two drugs, if any.

Study design: Prospective double blind study

Place and Duration of Study: Department of anaesthesiology Dr D.Y Patil medical college hospital and research centre Pimpri Pune Duration -Sept.2018 -sept 2021.

Methodology: This is prospective randomized double-blind study. 60 ASA I and II patients randomly divided into two groups group P and group E of 30 each of either sex in age group of 18-65 years posted for elective surgery under general anesthesia. Group P:(n-30) received 2.5mg/kg Propofol and Group E:(n-30) received 0.3mg/kg Etomidate for induction. vital parameters such as HR, SBP, DBP, MAP, and SPO2 recorded at baseline(T0), before induction(T1), after induction(T2), during laryngoscopy(T3) ,after intubation at 1min, 2min, 3min, 5min and at 10 min. Time of induction was taken as period between time of start of study drug till loss of eyelash reflex

Conclusion: Induction time between the two study groups was statistically insignificant. (p>0.05) The fall in heart rate at post induction(T2), at 1 min, 2 min after intubation in Group P as compared to Group E was statistically significant, fall in SBP, DBP and MAP at post induction(T2), at 1 min, 2 min, 3 min and 5 min after intubation in Group P as compared to Group E was statistically significant. Pain on injection was more with propofol. However, myoclonus was more with etomidate

Keywords: : Propofol, Etomidate, Laryngoscopy, endotracheal intubation

23 **1. INTRODUCTION**

24

25 Anesthesiologists' tools for maintaining airway integrity include endotracheal intubation and
26 laryngoscopy. Following its description by Rawbotham and Magill in 1921, endotracheal
27 intubation has become a vital aspect of the anaesthetic management and critical care of the
28 patient^[1].

29

30 Reid and Brace characterised the hemodynamic response to laryngoscopy and tracheal
31 intubation for the first time in 1940². Due to reflex sympathetic stimulation, direct
32 laryngoscopy and endotracheal intubation typically cause a cardiovascular stress response
33 characterised by hypertension and tachycardia. This response is brief, lasting less than 10
34 minutes and occurring 30 seconds after laryngoscopy and intubation³.

35

36 Hemodynamic stability, little respiratory side effects, and quick clearance are all desirable
37 qualities in a general anaesthesia induction drug. Presently Propofol and Etomidate are
38 popular as rapid acting inducing agents. Propofol, 2,6 diisopropylphenyl, is the most popular
39 induction agent with its characteristics of rapid and smooth induction and recovery,
40 decreased incidence of nausea and vomiting etc. while on the other side, it decreases blood
41 pressure, cardiac output, and systemic vascular resistance^{4,5} due to inhibition of sympathetic
42 vasoconstriction and impairment of baroreceptor reflex regulatory system^{6,7}.

43

Propofol

44

Propofol chemically 2,6-diisopropofol, one of the groups of alkyl phenols. These are oils at
45 room temperature, are insoluble in water and highly lipid soluble.

46

Metabolism:

47

Propofol is rapidly metabolized in liver by conjugation with glucuronide and sulphate,
48 produce water soluble compounds, which are excreted in the kidney. The metabolites of
49 propofol are inactive.

50

Kidneys and Lungs, are extrahepatic metabolism for propofol.

51

Pharmacokinetics:

52

- Initial distribution half-life of propofol is 2-8 minutes
- 53 ▪ Elimination half-life is 4-23hours.
- 54 ▪ Volume of distribution in central compartment is 20 -40 seconds.
- 55 ▪ Clearance of propofol is 1.5 – 2.2 litre/min.
- 56 ▪ Time of peak effect is 90-100seconds.
- 57 ▪ Pharmacokinetics of propofol is altered by various factors like sex, weight, age, co
58 morbidities and ongoing medication.

59

60

Etomidate

61

Etomidate is a carboxylate imidazole-containing molecule with hemodynamic stability, low
62 respiratory depression, and protective actions on the brain. It has no effect on sympathetic
63 nervous system, baroreceptor reflex regulatory system and it has an effect of increased
64 coronary perfusion even on patients with moderate cardiac dysfunction; this makes it an
65 induction agent of choice in cardiac disease patients.

66

Etomidate, imidazole derivative(R-(+)-pentylethyl-1H-imidazole-5 carboxylate sulfate),
67 molecular weight is 342.36 kg water insoluble and is unstable in a neutral solution.”

68

Solvents: 2mg/mL propylene glycol (35% by volume) solution with a pH of 6.9 lipid emulsion
69 to reduce some of the side effects of etomidate

70

Metabolism: Etomidate is metabolized in the liver by

71

- Ester hydrolysis primarily

72

- N-dealkylation.

73

The main metabolite is inactive. Only 2% of the drug is excreted unchanged, the rest being
74 excreted as metabolites by the kidney (85%) and in bile (13%)

75

76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128

Pharmacokinetics:

The kinetics of etomidate is best described by “An open three-compartment model”. The drug has an initial distribution half-life of 2.7 minutes, a redistribution half-life of 29 minutes, and an elimination half-life that varies from 2.9 to 5.3 hours. Clearance of etomidate by the liver is high (18 to 25 mL/kg/min). Etomidate is 75% protein bound. “In patients with cirrhosis, the volume of distribution is doubled, but clearance is normal; the result is an elimination half-life that is twice normal.”

Considering the common use of Propofol and Etomidate as an induction agent, this study is conducted to compare the effects of these two drugs on hemodynamic responses during induction and endotracheal intubation in a patient undergoing elective surgery under general anesthesia.

2. MATERIAL AND METHODS

After approval from medical ethics committee, Dr D Y Patil Medical College and Hospital, Pune, written informed consent taken from all the patients participating in the study. The study was carried out on sixty (60) patients ASA I and II undergoing elective surgeries under standard general anaesthesia. Unwilling patients, pregnant patients, patients with heart diseases were excluded from studies. 60 patients were divided into two groups of 30 each. Randomized, double blinded method was used for grouping the patients. The patients and investigator were not aware of the drugs given. Drugs were prepared and administered by the theatre anaesthesiologist who was not part of data collection or analysis.

- Group P:(n-30) received 2.5mg/kg Propofol iv given slowly for induction
- Group E:(n-30) received 0.3mg/kg Etomidate iv given slowly for induction.

The patients were kept nil per orally for 8 hrs. prior to surgery. On arrival in operation theatre standard anesthesia monitors including pulse oximeter, NIBP, ECG, etc. connected to the patient. Baseline vital parameters such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), and SPO2 recorded. (T0)

Premedication:

Patient was premedicated with Ondansetron 0.1 mg/kg i.v., inj. Midazolam 0.02 mg/kg i.v. and inj. Fentanyl 2 mcg/kg i.v. PREOXYGENATION Patient was pre-oxygenated with 100% oxygen for 3 minutes. All vital parameters were recorded again(T1).

For induction - group P received Inj. Propofol 2.5mg/kg i.v and group E received Inj. Etomidate 0.3mg/kg i.v. given over 30 sec. After induction of anesthesia hemodynamic parameters were recorded(T2). Time of induction was taken as period between time of start of study drug till loss of eyelash reflex. The choice of muscle relaxant will be Inj. succinylcholine(2mg/kg) given after administering induction agent. Laryngoscopy and tracheal intubation attempted with appropriate size of endotracheal tube. All vital parameters will be recorded again during Laryngoscopy. (T3) Proper placement of endotracheal tube was confirmed by capnography and bilateral auscultation of chest. Periodic monitoring of vital parameters carried out at 1, 2, 3, 5 and 10 minute intervals post intubation. Anesthesia maintained with Oxygen, Nitrous oxide (33:66) and Isoflurane, along with intermittent boluses of muscle relaxant inj. vecuronium i.v. 0.1mg/kg as and when required throughout the surgery. At the end of surgery, patient will be reversed with inj. Glycopyrrolate 0.008 mg/kg i.v. along with Inj. Neostigmine methyl sulphate 0.05mg/kg intravenously.


129
130
131
132

3. RESULTS AND DISCUSSION

TABLE NO.1 AGE AND WEIGHT

VARIABLE	GROUP P MEAN \pm SD	GROUP E MEAN \pm SD	P VALUE
AGE	35.9 \pm 10.39	36.37 \pm 9.525	0.857
WEIGHT	59.4 \pm 11.56	60.83 \pm 14.14	0.669

133



134

135 **Graph 1: Bar graph showing comparison of mean age and weight between two groups**

136 Table no.1 and graph 1 shows mean age and weight among two groups. There was no
137 statistically considerable difference in two study groups.

138


139

TABLE NO. 2 GENDER

			GROUP		Total
			GROUP P	GROUP E	
SEX	FEMALE	Count	15	13	28
		%	50.0%	43.3%	46.7%
	MALE	Count	15	17	32
		%	50.0%	56.7%	53.3%
Total		Count	30	30	60
		%	100.0%	100.0%	100.0%

140

CHI SQUARE = 0.067, P VALUE = 0.706



141

142

Graph 2: Bar graph showing gender distribution between two groups

143

Table no.2 and graph 2 shows gender wise distribution of cases in two study groups. There

144

was no statistically considerable difference in two study groups

145

146

147


148

TABLE NO. 3 ASA GRADING

			GROUP		Total
			GROUP P	GROUP E	
ASA	I	Count	15	14	29
		%	50.0%	46.6%	48.3%
	II	Count	15	16	31
		%	50.0%	53.4%	51.7%
Total		Count	30	30	60
		%	100.0%	100.0%	100.0%

149

CHI SQUARE = 0.001, P VALUE = 1.000



150

Graph 3: Bar graph showing ASA grade distribution of patients between the two study groups


153 Table no.3 and graph 3 show ASA grade wise distribution of cases in study groups. There
154 was no statistically considerable difference in two study groups. Patients belonging to ASA
155 grade I & II were only considered in the study.

156

TABLE NO.4 TIME OF INDUCTION

VARIABLE	GROUP P MEAN \pm SD	GROUP E MEAN \pm SD	P VALUE
INDUCTION TIME (SECS)	35.03 \pm 2.498	35.33 \pm 2.218	0.625

157



158

159

Graph 4: Bar graph showing induction time between two group

160

Table 4 and bar diagram 4 show induction time in Group P and Group E. Induction time

161

between the two study groups was statistically insignificant. ($p > 0.05$)

162

163

164

165


166

167

TABLE NO. 5 HEART RATE

VARIABLE	GROUP P MEAN \pm SD	GROUP E MEAN \pm SD	P VALUE
HR AT BASELINE T0	78.4 \pm 2.74	79.33 \pm 1.918	0.133
HR BEFORE INDUCTION T1	78.1 \pm 2.59	78.63 \pm 1.847	0.362
HR POST INDUCTION T2	68.10 \pm 6.48	71.73 \pm 2.016	*0.005
HR DURING LARYNGOSCOPY T3	72.97 \pm 1.99	73.87 \pm 3.181	0.194
HR AFTER INTUBATION 1 MIN	71.90 \pm 1.32	73.67 \pm 3.315	*0.009
HR AT 2 MINS	70.27 \pm 1.23	72.17 \pm 1.683	*0.001
HR AT 3 MINS	74.07 \pm 3.07	74.20 \pm 3.022	0.866
HR AT 5 MINS	77.93 \pm 1.23	78.33 \pm 1.493	0.262
HR AT 10 MINS	79.60 \pm 1.30	80.07 \pm 1.337	0.176

169



170

171


Graph 5

172

173 Table 5 and graph 5 show comparison of heart rate between two groups. In group P, HR
 174 decreased at post induction(T2) (68.10 \pm 6.48), at post intubation 1min (71.90 \pm 1.32) and at 2
 175 min (70.27 \pm 1.23) as compared to group E. It was statistically significant.

TABLE NO. 6 SBP

VARIABLE	GROUP P MEAN ± SD	GROUP E MEAN ± SD	P VALUE
SBP AT BASELINE T0	129.53 ± 3.048	128.53 ± 1.961	0.136
SBP BEFORE INDUCTION T1	128.00 ± 1.742	128.33 ± 1.900	0.482
SBP POST INDUCTION T2	107.80 ± 2.483	121.43 ± 1.960	*0.001
SBP DURING LARYNGOSCOPY T3	130.70 ± 1.119	131.40 ± 1.673	0.062
SBP AFTER INTUBATION 1 MIN	118.67 ± 1.988	130.93 ± 1.143	*0.001
SBP AT 2 MINS	111.80 ± 3.078	128.07 ± 3.542	*0.001
SBP AT 3 MINS	113.87 ± 3.598	126.60 ± 1.499	*0.001
SBP AT 5 MINS	120.90 ± 1.125	128.53 ± 1.479	*0.001
SBP AT 10 MINS	130.33 ± 0.922	130.80 ± 1.126	0.084



Graph 6


180 Table no 6 & Graph 6 show comparison in systolic blood pressure between two groups. In
 181 Group P, SBP decreased at post induction (T2) (107.80 ± 2.483), after intubation at 1 min
 182 (118.67 ± 1.988), at 2 mins (111.80 ± 3.078), at 3 mins (113.87 ± 3.598) & at 5 min
 183 (120.90 ± 1.125).as compared to group E. It was statistically significant.

184

TABLE NO. 7 DBP

VARIABLE	GROUP P MEAN \pm SD	GROUP E MEAN \pm SD	P VALUE
DBP AT BASELINE T0	70.53 \pm 3.319	71.60 \pm 2.749	0.180
DBP BEFORE INDUCTION T1	70.47 \pm 2.813	70.60 \pm 2.978	0.859
DBP POST INDUCTION T2	65.00 \pm 2.393	70.93 \pm 3.051	*0.001
DBP DURING LARYNGOSCOPY T3	79.07 \pm 2.227	79.80 \pm 2.941	0.281
DBP AFTER INTUBATION 1 MIN	70.20 \pm 2.592	78.20 \pm 2.483	*0.001
DBP AT 2 MINS	65.20 \pm 2.821	73.80 \pm 2.295	*0.001
DBP AT 3 MINS	64.40 \pm 2.660	74.37 \pm 2.076	*0.001
DBP AT 5 MINS	66.47 \pm 2.837	71.77 \pm 3.126	*0.001
DBP AT 10 MINS	72.00 \pm 2.913	72.30 \pm 3.042	0.698

185



186

187

Graph 7

188 Table no 7 & Graph 7 show comparison of Diastolic Blood Pressure between two groups. In
 189 Group P, DBP decreased at post induction (T2) (65.10 ± 2.393), after intubation at 1 min
 190 (70.20 ± 2.592), 2 mins (65.20 ± 2.821), 3 mins (64.40 ± 2.660), and 5 mins (66.47 ± 2.837) as
 191 compared to group E. It was statistically significant.


192

193

TABLE NO. 8 MAP

VARIABLE	GROUP P MEAN \pm SD	GROUP E MEAN \pm SD	P VALUE
MAP AT BASELINE T0	90.20 ± 2.33	90.57 ± 1.87	0.492
MAP BEFORE INDUCTION T1	89.64 ± 1.91	89.84 ± 2.01	0.695
MAP POST INDUCTION T2	79.26 ± 1.77	87.76 ± 2.04	*0.001
MAP DURING LARYNGOSCOPY T3	96.27 ± 1.57	97.00 ± 1.88	0.113
MAP AFTER INTUBATION 1 MIN	86.35 ± 1.85	95.77 ± 1.69	*0.001
MAP AT 2 MINS	80.73 ± 2.08	91.88 ± 2.00	*0.001
MAP AT 3 MINS	80.88 ± 2.00	91.77 ± 1.38	*0.001
MAP AT 5 MINS	84.61 ± 1.94	90.68 ± 2.16	*0.001
MAP AT 10 MINS	91.44 ± 1.99	91.80 ± 2.05	0.499

194



195

196

Graph 8

197

Table 8 & Graph 8 show comparison of Mean Arterial Pressure between two groups In

198

Group P - MAP decreased at post induction (T2) (79.26 ± 1.77), after intubation at 1 min

199

(86.35 ± 1.85), 2 mins (80.73 ± 2.08), 3 mins (80.88 ± 2), and 5 mins (84.61 ± 1.94) as compared

200

to group E. It was statistically significant.

201

TABLE NO. 9 SPO2

VARIABLE	GROUP P MEAN \pm SD	GROUP E MEAN \pm SD	P VALUE
SPO2 AT BASELINE T0	99.63 \pm 0.490	99.63 \pm 0.490	1.000
SPO2 BEFORE INDUCTION T1	99.63 \pm 0.490	99.60 \pm 0.498	0.795
SPO2 POST INDUCTION T2	99.60 \pm 0.498	99.63 \pm 0.490	0.795
SPO2 DURING LARYNGOSCOPY T3	99.63 \pm 0.490	99.60 \pm 0.498	0.795
SPO2 AFTER INTUBATION 1 MIN	99.60 \pm 0.498	99.63 \pm 0.490	0.795

SPO2 AT 2 MINS	99.60 ± 0.498	99.63 ± 0.490	0.795
SPO2 AT 3 MINS	99.60 ± 0.498	99.63 ± 0.490	0.795
SPO2 AT 5 MINS	99.60 ± 0.498	99.60 ± 0.498	1.000
SPO2 AT 10 MINS	99.63 ± 0.490	99.63 ± 0.490	1.000

202


203 Episodes of apnea were not observed in both the groups. There was no significant
204 difference in oxygen saturation data between two groups. Samples are matched with P >
205 0.05.

206

TABLE NO. 10 SIDE EFFECTS

	GROUP P (N=30)	GROUP E (N=30)	P VALUE
PAIN ON INJECTION	26 (86.7%)	7 (23.3%)	0.001*
MYOCLONUS	2 (6.7%)	23 (76.7%)	0.001*
PONV	2 (6.7%)	3 (10.0%)	1.000

207



208

209

Graph 9

210 Table no 10 and Graph 9 show side effects of study drugs. In Group P - 26 patients out of 30

211 had pain on injection (86.7%) whereas in group E - 7 patients out of 30 had pain (23.3%).

212 There was significant difference in incidence of pain on injection between the two groups.

213 Sample showed P value < 0.05.

214 In Group P - 2 patients out of 30 had myoclonus activity (6.7%), whereas in Group E- 23

215 patients out of 30 had myoclonus activity (76.7%). There was statistically significant

216 difference in incidence of myoclonus activity between the two groups. Sample showed P

217 value < 0.05.

218 In group P- 2 patients out of 30 had PONV (6.7%) whereas in Group E- 3 patients out of 30
219 had PONV (10%). There was no statistically significant difference in incidence of PONV
220 between the two groups. Sample showed P value > 0.05.

221

222 **Discussion**

223 The autonomic nervous system's baseline tone and baroreceptor reflex modulation of
224 autonomic outflow influence cardiac function and peripheral vascular resistance, allowing for
225 hemodynamic stability during anaesthesia induction. Propofol is an intravenous induction
226 agent which combines the desirable characteristics of smooth induction and rapid recovery
227 from anesthesia. Propofol also reduces preload, afterload and contractility which directly
228 effects on vascular smooth muscle and has venous dilating properties. It causes reduction in
229 tonic levels of sympathetic activity.

230 Etomidate's key characteristics, such as hemodynamic stability, little respiratory depression,
231 and favourable pharmacokinetics, allow for quick recovery after a single dose. Etomidate
232 causes reduction in myocardial function and basal sympathetic tone. It maintains
233 hemodynamic stability by preserving or augmenting baroreflex mechanisms.

234 **Demographic profile**

235 In the present study, there was no significant difference in demographic data between the
236 two groups in relation to Age, weight, gender, and ASA grades. Samples are matched with p
237 > 0.05. [Table 1,2 and 3].

238 **Hemodynamic Parameters**

239 **Baseline Parameters:**

240 In this study, the baseline values (before drug administration) of HR, SBP, DBP & MAP were
241 comparable in all two groups (p = 0.133, p = 0.136, p = 0.180, p = 0.492 respectively) i.e., p
242 value was not significant (p > 0.05).

243 For premedication, Inj Ondansetron 0.1mg/kg iv, Inj Midazolam 0.02mg/kg iv and Inj fentanyl
244 2mcg/kg iv was used in all the cases.

245 Selected patients were induced with either Inj propofol 2.5 mg/kg iv or inj. Etomidate 0.3 mg
246 iv according to the allocated groups.

247 Induction Time: According to our study the mean induction time in group P was 35.03 ±2.498
248 sec whereas in Group E was 35.33±2.218sec, which was statistically insignificant.

249 **Dr. Supriya Agarwal et al¹⁰** in 2020 conducted a comparative study between etomidate and
250 propofol as an induction agent during induction, laryngoscopy and intubation showed that
251 mean duration of time to loss of consciousness between two groups was statistically
252 insignificant.

253 Results of our study was similar to above mentioned study

254 **Haemodynamic parameters**

255 **Heart Rate:**

256 Table 5 and graph 5 shows comparison of HR between the two groups at baseline (T0),
257 before induction (T1), post induction (T2), during laryngoscopy (T3), after intubation at 1, 2,
258 3, 5 & 10min.

259 Our observations showed statistically significant difference in HR values at post induction
260 (T2), after intubation at 1min and 2 min

261 There was decrease in heart rate in group P as compared to group E at Post induction (T2)
262 group P (68.10±6.48) vs group E (71.73±2.016), at 1 min after intubation group P
263 (71.90±1.32) vs group E (73.67±3.315), at 2 min After intubation group P (70.27±1.23).vs
264 group E (72.17±1.683) and it was statistically significant with P<0.05.

265 The fall in heart rate at post induction(T2), at 1 min, 2 min after intubation in Group P as
266 compared to Group E was statistically significant with P value (<0.05).

267 **Djordjević B, Stojiljković M P. et al¹¹** in 1999 Jan-Feb, conducted a study to compare the
268 cardio vascular effects of induction doses of propofol, etomidate and thiopentone on total
269 165 female patients randomly divided into three groups each one received a different
270 anesthetic agent propofol 2.5 mg/kg (n=58), etomidate 0.3mg/kg (n=54) or thiopentone
271 5mg/kg (n=53) showed that slowing down of radial pulse was more marked in propofol, than
272 in etomidate or thiopentone group at 2 min, 5 min,10 min after induction of anesthesia.

273 The results of our study were similar to the one obtained by the above-mentioned study.

274 **Systolic Blood pressure**

275 In our study, SBP was compared between two groups at baseline (T0), before induction
276 (T1), post induction (T2), during laryngoscopy (T3), after intubation at 1, 2, 3, 5 & 10min

277 Our observations showed statistically significant difference in SBP values at post induction
278 (T2), after intubation at 1min and 2 min,3min and 5 min.

279 In our study, it was found that in group P at post induction(T2) mean SBP was 107.80±
280 2.483 whereas in Group E it was 121.43 ± 1.960, at 1 min after intubation in the Group P
281 mean SBP was 118.67±1.988 whereas in Group E it was 130.93±1.143, At 2 min after
282 intubation in the Group P mean SBP was 111.80± 3.078 whereas in Group E it
283 was 128.07±3.542, at 3min after intubation in the group P mean SBP was 113.87±3.598
284 whereas in Group E it was 126.6±1.499 and at 5 min after intubation in the Group P mean
285 SBP was 120.9 ±1.125 whereas in Group E it was 128.58± 1.479

286 The fall in SBP at post induction(T2), at 1 min, 2 min, 3 min and 5 min after intubation in
287 Group P as compared to Group E was statistically significant with P value (<0.05).

288 The following study shows similar results like our study

289 **Thomas J Elbert**¹² et al 1992 compared inj propofol 2.5mg/kg and etomidate 0.3mg/kg to
290 study the sympathetic response, and found that cardiac and baroslopes were well
291 maintained with etomidate but decreased with propofol. Haemodynamic stability was seen
292 more with etomidate due to preservation of sympathetic outflow and autonomic reflexes.

293 **Djordjević B, Stojilković MP** et al¹¹ in 1999 Jan-Feb. Conducted a study to compare the
294 cardio vascular effects of induction doses of propofol, etomidate and thiopentone on total
295 165 female scheduled for abortion patients randomly divided into three groups each one
296 received a different anestheshetic agent propofol 2.5 mg/kg (n=58), etomidate 0.3mg/kg
297 (n=54) or thiopentone 5mg/kg (n=53) showed significant greater decrease in blood pressure
298 was in propofol group than etomidate or propofol after induction at 2,5 and 10 min after
299 induction.

300 **P. Savanth Kumar, P Lokesh et al**¹³ in 2021 conducted a study on etomidate vursus
301 propofol for induction of general anesthesia, in this study group P comprised of 40 patients
302 induced with inj. Propofol 2mg/kg and group E comprised of 40 patients induced with
303 etomidate 0.3mg/kg. Study showed SBP decreased in propofol group from base line value at
304 1min,2min and 3 min of induction, at 1 min and 2 min of post intubation compared to group E
305 and it was statistically significant.

306 **Diastolic Blood Pressure**

307 In our study, the DBP was compared between two study groups at baseline (T0), before
308 induction (T1), post induction (T2), during laryngoscopy (T3), after intubation at 1, 2, 3, 5 &
309 10min.

310 Our observations showed statistically significant difference in DBP in group P compared to
311 group E at post induction (T2), after intubation at 1min and 2 min,3min and 5 min.

312 In group P at post induction (T2) mean DBP was 65.00 ± 2.393 whereas in group E it was
313 70.93 ± 3.051 , after intubation at 1 min in group P mean DBP was 70.20 ± 2.592 whereas in
314 group E it was 78.20 ± 2.483 , at 2min after intubation in group P mean DBP was $65.20 \pm$
315 2.821 whereas in group E it was 73.80 ± 2.295 , at 3min after intubation in group P mean DBP
316 was 64.40 ± 2.660 where as in group E it was 74.37 ± 2.076 and at 5 min after intubation in
317 group P mean DBP was 66.47 ± 2.837 whereas in group E it was 71.77 ± 3.126 [Table 6]

318 The fall in DBP at post induction(T2), at 1 min, 2 min, 3 min and 5 min after intubation in
319 Group P as compared to Group E was statistically significant with P value (<0.05).

320 Following study shows similar results like our study

321 **Shah, Jigna, et al**¹⁴. in 2018 conducted a "Comparative study of propofol vs etomidate as
322 an induction agent to evaluate hemodynamic changes during induction of anesthesia in
323 controlled hypertensive patients". Sixty patients undergoing surgery under general
324 anesthesia. 30 patients Group P were given inj fentanyl 2 mcg/kg, followed by inj propofol 1-
325 2 mg/kg; and patients of Group-E were given inj fentanyl 2 mcg/kg, followed by inj etomidate
326 0.2-0.4 mg/kg. The fall mean in DBP in group P from baseline compered to group E was
327 statistically significant at 1min ,3 min ,5 min and 10 min after induction.

328 **Mean Arterial Pressure**

329 In our study, the MAP was compared between two study groups at baseline (T0), before
330 induction (T1), post induction (T2), during laryngoscopy (T3), after intubation at 1, 2, 3, 5 &
331 10min.

332 Our observations showed statistically significant difference in MAP values at post induction
333 (T2), after intubation at 1min and 2 min,3min and 5 min.

334 In group P at post induction (T2) MAP was 79.26 ± 1.77 whereas in group E it was
335 87.76 ± 2.04 , after intubation at 1 min in group P MAP was 86.35 ± 1.85 whereas in Group E it
336 was 95.77 ± 1.69 , at 2min after intubation in group P MAP was 80.73 ± 2.08 whereas in
337 Group E it was 91.88 ± 2.00 , after intubation at 3 min in group P MAP was 80.88 ± 2.00
338 whereas in group E it was 91.77 ± 1.38 and at 5min after intubation in group P MAP was
339 84.61 ± 1.94 whereas in group E 90.68 ± 2.16 .

340 The fall in Mean Arterial Pressure, post induction(T2), at 1 min, 2 min, 3 min and 5 min after
341 intubation in Group P as compared to Group E was statistically significant with P value
342 (<0.05).

343 Following studies show similar results like our study

344 **Shah, Jigna, et al**¹⁴ in 2018 conducted a "Comparative study of propofol vs etomidate as an
345 induction agent to evaluate hemodynamic changes during induction of anesthesia in
346 controlled hypertensive patients". Sixty patients undergoing surgery under general
347 anesthesia were randomly divided into two equal groups. Patients of Group P were given inj
348 fentanyl 2 mcg/kg, followed by inj propofol 1-2 mg/kg; and patients of Group-E were given inj
349 fentanyl 2 mcg/kg, followed by inj etomidate 0.2 to 0.4 mg/kg. The fall in mean MAP in group
350 P compared to group E was statistically significant at 1min ,3 min ,5 min and 10 min after
351 induction.

352 **P. Savanth Kumar, P Lokesh et al**¹³ in 2021 conducted a study on etomidate versus
353 propofol for induction of general anesthesia , in this study group P comprised of 40 patients
354 induced with inj. propofol 2mg/kg and group E comprised of 40 patients induced with
355 etomidate 0.3mg/kg showed following induction, SBP, DBP and MAP decreased in propofol
356 group from base line value at 1min,2min and 3 min, etomidate group show stable SBP,DBP
357 and MAP at 1min, 2 min and 3 min of induction, at 1 min and 2 min of post intubation it was
358 statistically significant.

359 Etomidate is considered to be an ideal induction agent specially for cardiac patients and
360 small short-term surgeries.³⁸

361 The myocardial oxygen supply demand ratio is well maintained with Etomidate. It provides a
362 better safety during induction in patients at risk of cardiac disease with less cardiovascular
363 depression than propofol.³⁹

364 **Oxygen Saturation**

365 As per our study, there was no significant difference in oxygen saturation data between the
366 two groups. Samples are matched with $p > 0.05$. [Table 8]. The episodes of apnea were not
367 significant following induction and not associated with any fall in oxygen saturation.

368 **JC Song**¹⁵ **et al** 2015 in his randomized clinical trial of Etomidate Anesthesia during ERCP
369 Caused More Stable Haemodynamic Responses Compared with Propofol, in his study it
370 showed that no patient from etomidate or propofol group experienced desaturation or
371 apnea, oxygen saturation noted at point T0 = baseline values, 5 min after entering the
372 endoscopy room; T1 = 5 min after the patients received midazolam; T2= when BIS was 50
373 (after induction of etomidate or propofol); T3 = at scope intubation and T4-10 = by 5-min
374 intervals during the ERCP.

375 Results of our study are similar to above mentioned study

376 **Adverse effects**

377 On comparing the adverse effects Use of propofol was associated with increased pain on
378 injection than etomidate ($p < 0.05$). Out of 30 patients, 26 patients in group P had pain on
379 injection (86.7%) where as in group E- 7 patients out of 30 had pain on injection (23.3%)
380 [Table 9].

381 Our findings in consistent with finding of **Agarwal S et al**¹⁶ in 2016 who did a comparative
382 study between etomidate and propofol 100 patients undergoing general anesthesia, similar
383 findings observed in comparative study of the effects of Etomidate and propofol in patient
384 undergoing laparoscopic cholecystectomy conducted by **Zarina Wahab et al**¹⁷ in 2020

385 Use of etomidate was associated with high incidence of myoclonus than propofol (p
386 value < 0.05). Out of 30 patients 2 patients in group P had myoclonus activity (6.7%). In group
387 E 23 patients out of 30 had myoclonus activity (76.7%.) [Table 10]

388 **Fragen, Robert J.MD et al**¹⁸ in 1976 in his comparative study between Etomidate and
389 thiopental for induction of general anesthesia high incidence of myoclonia was seen with
390 etomidate. Myoclonus does not originate from an epileptic focus. It arises due to subcortical
391 disinhibition, leading to irritable leg syndrome during normal sleep. Myoclonus is
392 characterised by uncomfortable legs, irritability, disability to sleep and numbness, with
393 normal neurological examination.

394 **Fatma Saricaoglu et al**¹⁹ 2011 in his study comparison of etomidate-lipuro, propofol and
395 admixture at induction. 90 patients assigned into three groups; higher incidence of
396 myoclonus seen in etomidate-lipuro group

397 Findings of our study are similar findings of above-mentioned studies

398 In our study, incidence of nausea and vomiting higher in group E 3 out of 30 patients (10%)
399 as in group P 2 out of 30 patients (6.7%), although the difference was not statistically
400 insignificant our findings are similar to the finding of Kumar A et al²⁰ 2018 study on propofol
401 and etomidate as an anestheshetic agent for elective non cardiac surgery.

402
403

404 **4. CONCLUSION**

405

406 It is concluded that Propofol and etomidate are both safe anaesthetics. As an induction drug,
407 Etomidate retains superior haemodynamic stability than Propofol. Propofol caused increased
408 pain during injection. Etomidate, on the other hand, caused increased myoclonus. There
409 were no severe adverse effects or complications associated with either treatment.

410

411 **ETHICAL APPROVAL**

412

413 The authors of this study hereby declare that all experiments have been examined and
414 approved by the appropriate ethics committee and have therefore been performed in
415 accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

416

417 **Consent**

418 As per international standard or university standard, patient's written consent has been
419 collected and preserved by the author(s).

420

421 **ACKNOWLEDGEMENTS**

422

423 We thank all the all the senior and junior faculty for their expertise and assistance throughout
424 all aspects of our study. We also thank all the patients who were part of this research.

425 **COMPETING INTERESTS**

426

427 Dr Bhavini Shah and Dr Shweta Birajdar, the authors of this study, declare that no
428 competing interests exist.

429

430 **AUTHORS' CONTRIBUTIONS**

431

432 'Dr Bhavini Shah' designed the study. 'Dr. Shweta Birajdar' performed the statistical
433 analysis, wrote the protocol, and wrote the first draft of the manuscript. 'Dr Bhavini Shah' and
434 'Dr. Shweta Birajdar' managed the analyses of the study. Both authors read and approved
435 the final manuscript.

436

437

438

439 **REFERENCES**

440

- 441 1. Magill, Endotracheal Anesthesia: Proceedings of the Royal Society of Medicine.
442 1928;22(2): p985-989.
- 443 2. Ried IC, Brace DE - Irritation of the respiratory tract and its reflex effect upon heart; Surg
444 Gynaec and Obst; 1940:70: pg 157-162.
- 445 3. Stoelting RK, Circulatory changes during laryngoscopy and tracheal intubation: influence
446 of duration of laryngoscopy with or without lidocaine. Anesthesiology:1977; 47 pg 381-
447 841
- 448 4. Hugo Van Aken H, Meinshausen E, Prien T, et al. The influence of fentanyl and tracheal
449 intubation on the hemodynamic effects of anesthesia induction with propofol/N2O in
450 humans. Anesthesiology 1988; 68: pg 157-163.
- 451 5. Stoelting, Roberta L. Hinges, Katherine E. Marschall. Stoelting's Anesthesia and Co-
452 existing Disease. 5th Edition. Philadelphia: Churchill Livingstone, 2009.
- 453 6. Paris A, Philipp M. Tonner PH, et al. Activation of alpha 2B-adrenoceptors mediates the
454 cardiovascular effects of etomidate. Anesthesiology. 2003;99:889-895.
- 455 7. Morel J. Salard M, Castelain C, et al. Haemodynamic consequences of etomidate
456 administration in elective cardiac surgery: a randomized double-blinded study. Br J
457 Anesthesh. 2011; 107:503-509
- 458 8. Snell RS. The Respiratory System in the Head and Neck. In: Clinical Anatomy by
459 regions. 9th edition. Taylor C, editor. Lippincott Williams and Wilkins; Philadelphia:
460 2012;639-649.

- 461 9. Bishop MJ, Bedford RF, Kil HK. Physiologic and Pathophysiologic responses to
462 intubation. In: Benumof JL. Airway Management – Principles and Practise. 1st edition.
463 Mosby; New York: 1996;102-118
- 464 10. Dr. Agarwal Supriya, Sharma Vidushi et al A comparative study between Etomidate and
465 Propofol as an induction agent during induction, laryngoscopy and intubation,
466 International Journal of Medical and Biomedical Studies, 2020; Volume 4(12):165-167.
- 467 11. Djordjević B, Stojiljković MP, Loncar-Stojiljković D, Krivokapić D, Vojnosanit et al A
468 clinical comparison of Cardiovascular effects of induction doses of the intravenous
469 anesthetic, propofol, etomidate and thiopentone]. Pregl. 1999 Jan-Feb;56(1):15-19.
470 Serbian.
- 471 12. Ebert TJ, Muzi M, Berens R, et al. Sympathetic responses to induction of anesthesia in
472 humans with propofol or etomidate. Anesthesiology 1992; 76:725-733.
- 473 13. P. Savanth Kumar, P. Lokesh, Balad Karunakar et al A Study on Etomidate versus
474 Propofol for Induction of General Anesthesia-A Comparative Study International Journal
475 of Health and Clinical Research, 2021;4(8):101-107.
- 476 14. Shah Jigna, et al. Comparative study of propofol vs etomidate as an induction agent to
477 evaluate hemodynamic changes during induction of anesthesia in controlled hypertensive
478 patients. Anesthesia, Pain & Intensive Care: An international journal of anesthesiology,
479 pain management, intensive care & resuscitation, 2018; 22(3): 361-367.
- 480 15. Song JC, Lu ZJ, Jiao YF, Yang B, Gao H, Zhang J, Yu WF. Etomidate Anesthesia during
481 ERCP Caused More Stable Haemodynamic Responses Compared with Propofol: A
482 Randomized Clinical Trial. Int J Med Sci 2015; 12(7):559-565.
- 483 16. Aggarwal S, Goyal VK, Chaturvedi SK, Mathur V, Baj B, Kumar A. A comparative study
484 between propofol and etomidate in patients under general anesthesia. Braz J
485 Anesthesiol. 2016 May-Jun;66(3):237-241.
- 486 17. Wahab Z, Heisnam I, Nushrat M, et al. A comparative study of the effect of etomidate and
487 propofol induction on haemodynamic response and serum cortisol levels in patients
488 undergoing laparoscopic cholecystectomy. J. Evid. Based Med. Healthc. 2020; 7(4), 186-
489 190.
- 490 18. J. Fragen, Nancy Caldwell, Edward A. Brunner. Clinical use of Etomidate for
491 anestheshetic induction: A preliminary report. Anesthesia analgesia 1976; 55:730-731.
- 492 19. Fatma Saricoaglu, Sennur Uzun, Oguzhan Arun, Funda Arun, Ulku Aypar, et al. A clinical
493 comparison of etomidate –lipuro and admixture at induction. Saudi journal of anesthesia
494 2011; 5:62-66.
- 495 20. Kumar A, Shekhawat KK, Sharma R, et al. A comparison of propofol and etomidate as
496 anestheshetic agents for elective non-cardiac surgery. Int J Res Med Sci 2018;6
497 (10):3454-3460.
498